Loading patent…
AssigneesInstitut Pasteur, Institut National de la Sante et de la Recherche Medicale, Assistance Publique-Hopitaux de Paris
InventorsHüseyin Firat, Pierre Langlade-Demoyan, Etienne Vilmer, Franç is Lemonnier, Pierre Rohrlich, Patricia Yotnda
Estimating the term…
The invention concerns the optimisation of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans.
An isolated mutated immunogenic peptide consisting of the R9M wildtype peptide sequence (SEQ ID NO:1) mutated by substitution at P1 and/or P5 of the wildtype R9M peptide sequence, which consists of a peptide sequence selected from SEQ ID NOS:2 to 7.
Dependencies are inferred from the claim text.